TerminatedPhase 2

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

Stopped: Lack of Efficacy

United States29 participantsStarted 2006-04

Plain-language summary

Plasmin is expected to create a posterior vitreous detachment. The pharmacological creation of a posterior vitreous detachment may be beneficial in a variety of conditions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who would benefit from a posterior vitreous detachment, as determined by the evaluating ophthalmologist. Exclusion Criteria: * Presence of a posterior vitreous detachment in the study eye * History of vitrectomy in the study eye * Proliferative diabetic retinopathy in the study eye * Presence of media opacity that precludes quality examination of the vitreous and fundus.

What they're measuring

Presence of a Grade A Posterior Vitreous Detachment (PVD)

Timeframe: 14 Days

Trial details

NCT IDNCT00348439

SponsorBausch & Lomb Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-08

View on ClinicalTrials.gov More Vitreoretinal Traction Syndrome trials